Compare Amgen, Inc. (AMGN) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.5. The key difference: Amgen, Inc. pays a 2.77% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none. Which is the better fit depends on your goals.
| AMGN | VWO | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | — |
52-Week High | $388.16 | $61.24 |
52-Week Low | $271.18 | $49.54 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
VWO trades at $59.89, up 0.67% today, with a bullish technical signal from moving averages. The ETF offers broad emerging markets exposure with a low 0.06% expense ratio and a 2.4% dividend yield. Recent news highlights strong capital inflows into emerging markets and comparisons with peers like EEM, emphasizing VWO's cost advantage and exclusion of South Korean stocks due to index methodology.
The outlook for VWO is supported by diversification benefits and attractive valuations in emerging markets, but risks include geopolitical tensions and index composition gaps. Analyst sentiment is mixed, with performance heavily influenced by regional allocations and macroeconomic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
